The Modern Equine Vet
February 2024
Vol 14 Issue 2 2024
Click Here to View Table of Contents

News Notes

Equine Devices Successful at Creating Good Biological Concentrations for Regenerative Medicine

A recent study compared the concentrations of alpha-2-macroglobulin (A2M) in equine plasma samples processed by 3 commercial devices to be used as regenerative joint therapy for osteoarthritis.

The researchers tested the Alpha2EQ (Astaria), Pro-Stride APS (Zoetis) and Restigen PRP (Zoetis) devices. These devices produce a concentrated solution of cells, platelets, growth factors and anti-inflammatory cytokines to reduce pain and manage osteoarthritis.

They collected plasma from 13 healthy horses and used mass spectrometry to determine the protein concentrations in each sample. They selected a specific A2M peptide to act as a surrogate for the entire A2M protein, which contains several multifunctional proteins. A2M may promote healing in the joints because it inhibits protease and inflammatory cytokines by using an amino acid mechanism to trap them.

The study was done in partnership with the University of Pennsylvania, University of Colorado and Zoetis. The Zoetis Animal Health Research and Development team completed the mass spectrometry plasma protein analysis in Kalamazoo, Mich.

The researchers found the plasma output volume, A2M concentration and plasma protein composition were equivalent among the 3 devices (P>0.05). The 30 mLs of plasma generated by the Pro-Stride APS and Restigen PRP devices contained the same concentrations of 16 plasma proteins (including A2M) as the final output of the Alpha2EQ device.

In addition to the platelet-derived growth factors and white blood cell derived anti-inflammatory cytokines contained in the cellular output of Pro-Stride and Restigen, the A2M concentration was significantly higher than the final plasma output of Alpha2EQ (P>0.0001).

The results help support the understanding of the components of each device, according to Kyla Ortved, DVM, PhD, DACVS, DACVSMR, an associate professor of large animal surgery, University of Pennsylvania School of Veterinary Medicine “Managing osteoarthritis calls for a comprehensive mix of plasma proteins, anti-inflammatory cytokines and anabolic growth factors,” Dr. Ortved explained.

Osteoarthritis is a complex biologic process that affects many horses as they age. A targeted approach that takes on multiple disease pathways is needed to help manage pain and promote healing.

“This research provides guidance for equine veterinarians seeking a comprehensive option to help manage osteoarthritis for horses entrusted in their care,” said Nathan Voris, MD, the director of Equine Technical Services at Zoetis, which makes these devices.

Regenerative therapies have been shown to improve a horse’s lameness grade for up to 1 year after a single injection, and in some cases even longer. With these devices, processing can take place right at the farm, stable or clinic. MeV

For more information:
Ortved KF, Alward L, Cowles B, et al. Use of quantitative mass spectrometry-based proteomics and ELISA to compare the alpha 2 macroglobulin concentration in equine blood-based products processed by three different orthobiologic devices. Front Vet Sci. 2024 Feb. 9. https://www.frontiersin.org/articles/10.3389/fvets.2024.1335972/full